Trial Profile
Phase I-II Non-Randomized Study of Yttrium 90 Ibritumomab Tiuxetan (Zevalin) With Non Myeloablative Allogeneic Stem Cell Transplantation in Patients With Relapsed, Refractory, or Transformed Indolent Non Hodgkin Lymphoma.
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Ibritumomab tiuxetan (Primary) ; Cyclophosphamide; Fludarabine; Rituximab
- Indications Graft-versus-host disease; Non-Hodgkin's lymphoma
- Focus Adverse reactions; Therapeutic Use
- 16 Dec 2008 New trial record.